ATE353082T1 - Inhibitoren der gpib-vwf wechselwirkung - Google Patents
Inhibitoren der gpib-vwf wechselwirkungInfo
- Publication number
- ATE353082T1 ATE353082T1 AT03740199T AT03740199T ATE353082T1 AT E353082 T1 ATE353082 T1 AT E353082T1 AT 03740199 T AT03740199 T AT 03740199T AT 03740199 T AT03740199 T AT 03740199T AT E353082 T1 ATE353082 T1 AT E353082T1
- Authority
- AT
- Austria
- Prior art keywords
- gpib
- compounds
- inhibitors
- formula
- vwf
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02012590A EP1369420A1 (en) | 2002-06-06 | 2002-06-06 | Inhibitors of the GPib - vWF interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353082T1 true ATE353082T1 (de) | 2007-02-15 |
Family
ID=29433122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03740199T ATE353082T1 (de) | 2002-06-06 | 2003-06-06 | Inhibitoren der gpib-vwf wechselwirkung |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1369420A1 (enExample) |
| JP (1) | JP4455326B2 (enExample) |
| AT (1) | ATE353082T1 (enExample) |
| AU (1) | AU2003274686A1 (enExample) |
| BR (1) | BR0311826A (enExample) |
| CA (1) | CA2488193A1 (enExample) |
| DE (1) | DE60311578T2 (enExample) |
| MX (1) | MXPA04011408A (enExample) |
| WO (1) | WO2003104221A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1606247A1 (en) * | 2003-03-14 | 2005-12-21 | H. Lundbeck A/S | Substituted aniline derivatives |
| AR043507A1 (es) * | 2003-03-14 | 2005-08-03 | Lundbeck & Co As H | Derivados de anilina sustituidos y composiciones farmaceuticas |
| EP1669348A4 (en) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| WO2006016548A1 (ja) * | 2004-08-09 | 2006-02-16 | Eisai R & D Management Co., Ltd. | ヘテロ環化合物を含有する新規な抗マラリア剤 |
| JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| EP2065377B1 (en) | 2006-09-21 | 2011-11-23 | Eisai R&D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| CN102702185A (zh) | 2007-04-27 | 2012-10-03 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的盐的结晶 |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2009005638A2 (en) | 2007-06-27 | 2009-01-08 | Merck & Co., Inc. | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| US8188119B2 (en) | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
| CN103327972A (zh) * | 2010-10-11 | 2013-09-25 | 里兰斯坦福初级大学理事会 | 取代的苯甲酰胺及其用途 |
| SG11201406518XA (en) | 2012-04-12 | 2014-11-27 | Univ Leland Stanford Junior | Substituted benzamides and their uses |
| JP2023078557A (ja) * | 2021-11-26 | 2023-06-07 | 学校法人東海大学 | フォンヴィルブランド因子と血小板との結合を阻害するための医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW301607B (enExample) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| AU5812498A (en) * | 1996-12-20 | 1998-07-17 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
-
2002
- 2002-06-06 EP EP02012590A patent/EP1369420A1/en not_active Withdrawn
-
2003
- 2003-06-06 DE DE60311578T patent/DE60311578T2/de not_active Expired - Lifetime
- 2003-06-06 AU AU2003274686A patent/AU2003274686A1/en not_active Abandoned
- 2003-06-06 EP EP03740199A patent/EP1509516B1/en not_active Expired - Lifetime
- 2003-06-06 JP JP2004511291A patent/JP4455326B2/ja not_active Expired - Fee Related
- 2003-06-06 BR BR0311826-6A patent/BR0311826A/pt not_active IP Right Cessation
- 2003-06-06 WO PCT/EP2003/005955 patent/WO2003104221A1/en not_active Ceased
- 2003-06-06 AT AT03740199T patent/ATE353082T1/de not_active IP Right Cessation
- 2003-06-06 MX MXPA04011408A patent/MXPA04011408A/es unknown
- 2003-06-06 CA CA002488193A patent/CA2488193A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60311578T2 (de) | 2007-11-15 |
| JP4455326B2 (ja) | 2010-04-21 |
| EP1509516B1 (en) | 2007-01-31 |
| WO2003104221A1 (en) | 2003-12-18 |
| AU2003274686A8 (en) | 2003-12-22 |
| AU2003274686A1 (en) | 2003-12-22 |
| DE60311578D1 (de) | 2007-03-22 |
| JP2005528459A (ja) | 2005-09-22 |
| BR0311826A (pt) | 2005-03-29 |
| EP1509516A1 (en) | 2005-03-02 |
| EP1369420A1 (en) | 2003-12-10 |
| MXPA04011408A (es) | 2005-09-30 |
| CA2488193A1 (en) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE353082T1 (de) | Inhibitoren der gpib-vwf wechselwirkung | |
| ATE250590T1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| CY1107871T1 (el) | Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2 | |
| EA200500595A1 (ru) | Новые алкиновые соединения, обладающие антагонистическим в отношении мсн действием, и содержащие эти соединения лекарственные средства | |
| CY1109886T1 (el) | Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες | |
| DE69034103D1 (de) | Imidazoalkensäure | |
| ES2060951T5 (es) | Azaindenos. | |
| DK0539086T3 (da) | Kondenserede pyrimidinderivater og deres anvendelse som angiotensin II-antagonister | |
| HRP20050383A2 (en) | Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds | |
| DE60330757D1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| CY1108190T1 (el) | Ανασυνδυασμενος υποδοχεας κολλαγονου αιμοπεταλιων της γλυκοπρωτεϊνης vi και η φαρμακευτικη του χρηση | |
| ATE413388T1 (de) | Muskarin antagonisten | |
| BR0208741A (pt) | Derivados de piperidina | |
| CY1105879T1 (el) | Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| NO20053762L (no) | Kondensert furanforbindelse. | |
| PE20010751A1 (es) | Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos | |
| HUP0500034A2 (hu) | N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
| ATE119524T1 (de) | Substituierte n-(imidazolyl)alkyl-alanin- derivate. | |
| DE60119368D1 (de) | Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
| BG101867A (bg) | Бензотиазиндиоксиди като антагонисти на ендотелин | |
| CY1105039T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ | |
| UY28689A1 (es) | Nuevos compuestos amida con actividad antagonista de mch y medicamentos que contienen estos compuestos. | |
| UY28790A1 (es) | Nuevos compuestos b(eta)-cetoamida con efecto antagonistico de mch y medicamentos que contienen estos compuestos | |
| ATE383343T1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
| NO20052413L (no) | Substituted aralkyl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |